LTBP4 and Duchenne muscular dystrophy: In summary, our data highlight SPP1 rs11730582 as a genetic modifier of the long-term effect of GCs treatment in Chinese patients with Duchenne muscular dystrophy, but do not indicate a previously reported association between LTBP4 haplotype and disease progression.